Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Romiplostim: A Bridge To Splenectomy In Three Patients With Refractory Immune Thrombocytopenia (ITP)

Dhaval Shah, MD, Siayareh Rambally, MD, Martha Mims, MD, Mark M. Udden, MD

Blood (2013) 122 (21): 4763.

https://doi.org/10.1182/blood.V122.21.4763.4763

Published: 2013

Journal Articles

Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival

Gustavo A. Rivero, MD, Maria Otazo, Sarvari Venkata Yellapragada, MD, Ang Li, Matthew Zheng, Ruben Hernandez Perez, Martha Mims, MD

Blood (2013) 122 (21): 5233.

https://doi.org/10.1182/blood.V122.21.5233.5233

Published: 2013

Journal Articles

Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)

Rui Li, MD, PhD, Matthew Zheng, Sarvari Venkata Yellapragada, MD, Ruben Hernandez Perez, Martha Mims, MD, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 5235.

https://doi.org/10.1182/blood.V122.21.5235.5235

Published: 2013

Journal Articles

Selective-Serotonin-Reuptake-Inhibitors (SSRIs) In Combination With Myeloma Directed Therapy Accelerates Sentinel M-Protein Normalization In De-Novo Multiple Myeloma

Mathew Zheng, Sarvari Venkata Yellapragada, MD, Martha Mims, MD, Ruben Hernandez Perez, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 5387.

https://doi.org/10.1182/blood.V122.21.5387.5387

Published: 2013

Journal Articles

Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides

Ruben Hernandez Perez, Ang Li, Sarvari Venkata Yellapragada, MBBS, MD, Matthew Zheng, Maria Otazo, Martha Mims, MD, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 1537.

https://doi.org/10.1182/blood.V122.21.1537.1537

Published: 2013

Journal Articles

Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Anjali Advani, MD, Shannon McDonough, Steven Coutre, MD, Brent L. Wood, MD, PhD, Jerald P. Radich, MD, Martha Mims, MD, Margaret O'Donnell, M.D., F.R.C.P.C., Stephanie Elkins, MD, Michael W. Becker, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD

Blood (2012) 120 (21): 2603.

https://doi.org/10.1182/blood.V120.21.2603.2603

Published: 2012

Journal Articles

Significant Improvement in Overall Survival Among Patients Diagnosed with Low-Risk Myelodysplastic Syndrome (MDS) Treated with Selective-Serotonin-Reuptake-Inhibitors (SSRIs)

Ang Li, Sarvari Venkata Yellapragada, MD, Martha Mims, MD, Gustavo A. Rivero, MD

Blood (2012) 120 (21): 3818.

https://doi.org/10.1182/blood.V120.21.3818.3818

Published: 2012

Journal Articles

Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins

Catherine M. Bollard, MD, Stephen Gottschalk, Andrea M. Sheehan, MD, George Carrum, MD, Hao Liu, PhD, Barbara Pro, MD, Luis Fayad, MD, Anas Younes, MD, Martha Mims, MD, Adrian P. Gee, PhD, Malcolm K. Brenner, MB, PhD, FRCP, FRCPath, Cliona M. Rooney, PhD, Helen E. Heslop, MD

Blood (2011) 118 (21): 956.

https://doi.org/10.1182/blood.V118.21.956.956

Published: 2011

Journal Articles

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

Concetta Quintarelli, Gianpietro Dotti, Sayyeda T. Hasan, Biagio De Angelis, Valentina Hoyos, Santa Errichiello, Martha Mims, Luigia Luciano, Jessica Shafer, Ann M. Leen, Helen E. Heslop, Cliona M. Rooney, Fabrizio Pane, Malcolm K. Brenner, Barbara Savoldo

Blood (2011) 117 (12): 3353–3362.

https://doi.org/10.1182/blood-2010-08-300376

Published: 2011

Includes: Supplemental data

Journal Articles

Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas

Catherine M Bollard, MD, Gianpietro Dotti, MD, Stephen Gottschalk, Enli Liu, MD, MS, Andrea Sheehan, MD, Martha Mims, MD, Hao Liu, PhD, Adrian P. Gee, PhD, Malcolm K. Brenner, MB, PhD, FRCP, FRCPath, Helen E. Heslop, MD, Cliona M Rooney, PhD

Blood (2010) 116 (21): 560.

https://doi.org/10.1182/blood.V116.21.560.560

Published: 2010

Journal Articles

The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies

Barbara Savoldo, MD, PhD, Carlos A. Ramos, MD, Catherine M. Bollard, MBChB, MD, Enli Liu, MD, MS, Martha Mims, MD, Michael Keating, MD, Adrian P. Gee, PhD, Zhuyong Mei, MD, Cliona M Rooney, PhD, Helen E Heslop, MD, Malcolm K. Brenner, MB, PhD, FRCP, FRCPath, Gianpietro Dotti, MD

Blood (2010) 116 (21): 3949.

https://doi.org/10.1182/blood.V116.21.3949.3949

Published: 2010

Journal Articles

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

Concetta Quintarelli, Gianpietro Dotti, Biagio De Angelis, Valentina Hoyos, Martha Mims, Luigia Luciano, Helen E. Heslop, Cliona M. Rooney, Fabrizio Pane, Barbara Savoldo

Blood (2008) 112 (5): 1876–1885.

https://doi.org/10.1182/blood-2008-04-150045

Published: 2008

Includes: Supplemental data

NARROW

Romiplostim: A Bridge To Splenectomy In Three Patients With Refractory Immune Thrombocytopenia (ITP)

Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival

Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)

Selective-Serotonin-Reuptake-Inhibitors (SSRIs) In Combination With Myeloma Directed Therapy Accelerates Sentinel M-Protein Normalization In De-Novo Multiple Myeloma

Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides

Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Significant Improvement in Overall Survival Among Patients Diagnosed with Low-Risk Myelodysplastic Syndrome (MDS) Treated with Selective-Serotonin-Reuptake-Inhibitors (SSRIs)

Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas

The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only